Trump Media and Technology Group Corp vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Trump Media and Technology Group Corp trades at $8.11 (market cap $2.28B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 11.1× Trump Media and Technology Group Corp's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| DJT | RPRX | |
|---|---|---|
Market Cap | $2.28B | $25.27B |
Volume | 3,148,379 | 3,671,183 |
Sector | Media | Health |
52-Week High | $16.56 | $63.96 |
52-Week Low | $7.06 | $35.44 |
Typical Hold Time | 17 Days | 1 Days |
Enterprise Value | $2.35B | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.20, down 0.24% with a bearish technical signal. The company reported $3.68M revenue for 2025 but a net loss of $712M, reflecting negative margins. Cash flow trends show heavy investing outflows partially funded by financing. Recent news highlights a proposed merger with TAE Technologies and insider selling activity.
Outlook remains challenged by persistent losses and high valuation multiples. The merger with TAE offers strategic diversification but execution risk is high. Investor sentiment is cautious amid weak fundamentals and negative profitability trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →